Martin Robert C G, Cannon Robert M, Brown Russell E, Ellis Susan F, Williams Sharon, Scoggins C R, Abbas Abbas E
University of Louisville, Department of Surgery, Division of Surgical Oncology, Louisville, Kentucky, USA; Department of Surgery, Ochsner Medical Center, Ochsner Health Systems, New Orleans, Louisiana, USA.
Oncologist. 2014 Mar;19(3):259-65. doi: 10.1634/theoncologist.2013-0344. Epub 2014 Feb 24.
To determine whether self-expanding plastic stent (SEPS) placement significantly improves quality of life and maintains optimal nutrition while allowing full-dose neoadjuvant therapy (NAT) in patients with esophageal cancer.
A prospective, dual-institution, single-arm, phase II (http://ClinicalTrials.gov: NCT00727376) evaluation of esophageal cancer patients undergoing NAT prior to resection. All patients had a self-expanding polymer stent placed prior to NAT. The European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-OG25, Functional Assessment of Cancer Therapy-Anorexia, and Functional Assessment of Cancer Therapy-General surveys were administered prior to stenting, within 1 week post-stent placement, and at the completion of neoadjuvant therapy.
Fifty-two patients were enrolled; 3 (5.8%) had stent migrations requiring replacement. There were no instances of esophageal erosion or perforation. All patients received some form of neoadjuvant therapy. Thirty-six (69%) received chemoradiation; 34 (93%) of these patients received the planned dose of chemotherapy, and 27 (75%) received the full planned dose of radiotherapy. There were 16 (31%) patients receiving chemotherapy alone; 12 (74%) of patients in the chemotherapy-alone group completed the planned dose of therapy.
Placement of SEPS appears to provide significant improvement in quality of life related to dysphagia and eating restriction in patients with esophageal cancer undergoing neoadjuvant therapy. Consideration of SEPS instead of percutaneous feeding tube should be initiated as a first line in dysphagia palliation and NAT nutritional support.
确定自膨式塑料支架(SEPS)置入术是否能显著改善食管癌患者的生活质量并维持最佳营养状态,同时允许患者接受全剂量新辅助治疗(NAT)。
一项前瞻性、双机构、单臂、II期(http://ClinicalTrials.gov: NCT00727376)评估,针对在切除术前接受NAT的食管癌患者。所有患者在接受NAT前均置入了自膨式聚合物支架。在置入支架前、置入支架后1周内以及新辅助治疗完成时,对患者进行欧洲癌症研究与治疗组织QLQ-C30和QLQ-OG25量表、癌症治疗功能评估-厌食量表以及癌症治疗功能评估-一般量表的调查。
共纳入52例患者;3例(5.8%)发生支架移位,需要更换支架。未发生食管糜烂或穿孔情况。所有患者均接受了某种形式的新辅助治疗。36例(69%)接受了放化疗;其中34例(93%)患者接受了计划剂量的化疗,27例(75%)患者接受了全计划剂量的放疗。16例(31%)患者仅接受化疗;在仅接受化疗的患者组中,12例(74%)完成了计划剂量的治疗。
对于接受新辅助治疗的食管癌患者,SEPS置入术似乎能显著改善与吞咽困难和饮食限制相关的生活质量。在吞咽困难姑息治疗和NAT营养支持方面,应首先考虑使用SEPS而非经皮饲管。